Veracyte Q4 revenue $118.6M (+21%), net income $5.1M vs. loss a year ago

VERACYTE, INC.

2024-FY EPS reported $0.31 revenue$445,764,000

Q4 total revenue $118.6M (+21%), testing revenue $112.2M (+24%), testing volume +25% to 39,107 tests.
Q4 net income $5.1M vs. net loss in Q4 2023; adjusted EBITDA $26.1M (22.0% margin), up 76%.
Full-year 2024 revenue $445.8M (+23%), net income $24.1M vs. 2023 loss; adj. EBITDA $91.9M (20.6%).
Decipher revenue +44% in Q4, volume +45% to >22,400 tests; Afirma revenue +4%, volume +8%.
Cash from operations $75.1M in 2024; ended with $289.4M cash & short-term investments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.